Intermediate Capital Share Discussion Threads

[chinese investor] 28/5/2024 07:45

My Share For 2024 !

[p49b] 28/5/2024 07:23

The Board has proposed a final dividend of 53.2p per share which, combined with the interim dividend of 25.8p per share, results in total dividends for the year of 79.0p (FY23: 77.5p). This marks the 14th consecutive year of increases in our ordinary dividend per share, which over the last five years has grown at an annualised rate of 12%. We continue to make the dividend reinvestment plan available.

[chinese investor] 28/5/2024 07:21

Final Ordinary Dividend 53.2p
Interim Ordinary Dividend 25.8p

Total 79p

[its the oxman] 28/5/2024 07:06

Strong results eps, fum, etc Div increase only slight disappointment. That said targets outlined to raise 55bn over next 4 years shows how much growth is to come and should justify a continued increase in the share price. Morning presentation to come as well.

[zeppo] 28/5/2024 07:06

Mystified by dividend announcement.

Is 79p the final dividend or the annual dividend.

My records may be wrong ut there are two dividends per year, are there not?

[chinese investor] 28/5/2024 07:02

that'll do nicely

[zeppo] 28/5/2024 06:52

Tag57

Agreed!

[tag57] 28/5/2024 06:37

Results look pretty decent but divi increase to 79p disappointing given results.

[dustinthyme] 27/5/2024 17:55

hxxps://theoakbloke.substack.com/p/icg-enterprise-trust-lonicgt

[pvb] 27/5/2024 12:39

The rising price leading up to the results (28th may) suggests expectation of strong results. We shall soon find out whether justified or not!

[mirandaj] 27/5/2024 07:22

Canaccord Genuity reiterated their buy rating on 21st May in a research note  - £30.36

Interesting to see what happens this week.

[zeppo] 23/5/2024 11:30

More from this amazing company!

Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion, led by ICG Life Sciences team, to accelerate and expand first-of-its-kind antigen modulation technology
Brings total Series B funds raised to nearly $100 million
Proceeds to support broadening scope of ongoing clinical trial of GRWD5769; first clinical data to be reported at ASCO 2024
Company to expand R&D efforts to develop disease-modifying therapies for autoimmune disorders
Grey Wolf Therapeutics, a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation therapies to address the source of immune dysfunction in oncology and autoimmunity, today announced the closing of an oversubscribed $50 million Series B financing expansion, bringing the total amount of Series B funds raised to $99 million. The Series B expansion round was led by ICG’s Life Sciences team and included further investment from existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and British Patient Capital.

Proceeds from the round will be leveraged to broaden the scope of the company’s ongoing Phase 1/2 clinical trial of its lead immuno-oncology candidate, GRWD5769, in a range of solid tumour types. The funding also enables the company to expand research and development (R&D) for its versatile antigen modulation approach into treatments for autoimmune disease indications.
 
Tracy Weightman, Associate Director at ICG, said:

"Grey Wolf is an exciting growth stage UK biotechnology company with a novel and differentiated approach that has the potential to transform the lives of millions of patients globally. This investment demonstrates our commitment to building leading biotechnology companies and enabling them to compete on a global stage. We are pleased to support Grey Wolf through the next stage of its growth journey, enabling the company to advance its clinical development strategy and expand into new therapeutic areas."

[zeppo] 22/5/2024 18:57

hxxps://www.icgam.com › 2024 › 05 › 22 › icg-and-teras-launch-templus-the-first-southern-europe-regional-data-centre-platform

ICG and Teras launch Templus, the first Southern Europe regional data ...
Today

Templus utilises a new business model premised on infrastructure's close-to-end customers, digital security, and the highest standards of sustainability and energy efficiency.

ICG, the global alternative asset manager, and Teras Capital (" Teras "), the investment platform led by successful digital

This and Full Year Results on 28th May: Wow!

[scottishfield] 21/5/2024 11:47

JPMorgan raises Intermediate Capital Group price target to 2,798 (2,277) pence 'overweight'

[its the oxman] 20/5/2024 16:53

No idea re ticker I'm afraid. Seems a bit pointless but there we are.Results fairly close now and aum should be up well over 20% since May 2022 results when the shares almost reached 2500p. Performance fees might not be as much but if the outlook is positive and strong prospects or growth targets are reiterated along with a decent increase in the dividend then why not a new high.

[zeppo] 16/5/2024 20:33

Big dividend increase and this level may be sustained.

[growthpotential] 16/5/2024 19:26

Not sure, possibly great results already priced in. However, will let my winners run, as I also tend to hold my losers!

[pvb] 16/5/2024 17:13

Now over £22 going towards the results on 28th May. Can it be sustained?

[pvb] 14/5/2024 18:26

Europe and UK at an Inflection Point
13 May 2024

[growthpotential] 14/5/2024 14:58

Why did they change the ticker? Big deal

[mirandaj] 12/5/2024 15:40

After results



"4-7 June 2024
InterContinental Hotel, Berlin

SuperReturn International is private capital’s most senior gathering, with attendees from 70+ countries and a quality and quantity of LPs and GPs that can’t be found elsewhere."

[its the oxman] 07/5/2024 19:13

End of month, 28th

[growthpotential] 07/5/2024 18:42

When are the results?

[its the oxman] 06/5/2024 18:35

Based on 6 Wall Street analysts offering 12 month price targets for Intermediate Capital in the last 3 months. The average price target is 2,370.00p with a high forecast of 2,600.00p and a low forecast of 2,250.00p. The average price target represents a 10.13% change from the last price of 2,152.00p.Let's go for the high forecast. ?